HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICCR meeting outcome

This article was originally published in The Rose Sheet

Executive Summary

FDA announces the availability of a document detailing the outcome of the International Cooperation on Cosmetic Regulation meeting, held in Brussels in September, in a March 7 Federal Register 1notice. The announcement is in keeping with FDA's commitment to transparency, and the agency will accept comments on the document until July 2, 2008. Cosmetic labeling and nanotechnology were among the issues discussed at the meeting, which included regulators from the U.S., Canada, the EU and Japan (2"The Rose Sheet" Oct. 15, 2007, p. 4)...

You may also be interested in...



ICCR Addresses Cosmetic Labeling, Nanotechnology At First Meeting

The International Cooperation on Cosmetics Regulation invites the cosmetics industry to generate and submit data showing that U.S. consumers understand the meaning of "trivial names" on product labeling

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.

UsernamePublicRestriction

Register

RS015289

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel